Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2021
Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding DomainGrace Mantus, Lindsay E Nyhoff, Robert C Kauffman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2022
The Coronavirus Disease 2019 Pandemic Unmasked the Challenges Faced by Early-Stage Faculty in Infectious Diseases: A Call to ActionErin M Scherer, Martin Backer, Karen Carvajal, et al.
The Journal of Infectious Diseases|March 27, 2024
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US AdultsCarol M Kao, Christina A Rostad, Lauren E Nolan, et al.
Vaccine|October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adultsVarun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trialNadine Rouphael, Shahida Baqar, Michelle Dickey, et al.
Nature Biotechnology|August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensFrank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Science Immunology|June 13, 2020
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Frontiers in Public Health|December 10, 2021
Application of SARS-CoV-2 Serology to Address Public Health PrioritiesAmy C Sherman, Teresa Smith, Yerun Zhu, et al.
Plos Pathogens|September 15, 2016
Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine DesignJoseph G Jardine, Devin Sok, Jean-Philippe Julien, et al.
Pageof 4